Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 5:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: GlucaGen Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes

NCT05794581
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
CT-868, Placebo, Victoza
Drug
Lead sponsor
Carmot Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Sep 12, 2026, 5:07 AM EDT
Recruiting Phase 2 Interventional

Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial

NCT07202247
View directory record Official record
Conditions
Prostate Carcinoma, Recurrent Prostate Carcinoma
Interventions
Antiandrogen Therapy, Behavioral Intervention, Biospecimen Collection, Cardiac Computerized Tomographic Angiography, Computed Tomography, Electronic Health Record Review, Internet-Based Intervention, Lifestyle Counseling, Medical Device Usage and Evaluation, Nutritional Intervention, Questionnaire Administration, Radiation Therapy, Referral, Semaglutide, Short-Term Fasting, Tirzepatide
Drug · Behavioral · Procedure + 2 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
30 Years to 79 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 12, 2026, 5:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

GLP1R Polymorphisms and Response to GLP1

NCT00588380
View directory record Official record
Conditions
Diabetes
Interventions
GLP-1
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 40 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 18, 2011 · Synced Sep 12, 2026, 5:07 AM EDT
Recruiting Not applicable Interventional

Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation

NCT07387796
View directory record Official record
Conditions
Drug Discontinuation, Substance Use Disorders, Eating Behavior Changes, Tirzepatide
Interventions
Discontinuation and Reinitiation of Tirzepatide
Other
Lead sponsor
The University of Texas at Dallas
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 12, 2026, 5:07 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

GLP-1 and Hypoglycemia

NCT01858896
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Glucagon-Like Peptide- 1 (GLP-1) infusion, Placebo Comparator: Saline Infusion
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Sep 12, 2026, 5:07 AM EDT
Suspended Phase 4 Interventional

Effects of DPP-4 Inhibition on Triglycerides

NCT01527747
View directory record Official record
Conditions
Type 2 Diabetes, Hypertriglyceridemia
Interventions
Saxagliptin
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Sep 12, 2026, 5:07 AM EDT
Completed Phase 4 Interventional Results available

Short Bowel Syndrome and Teduglutide Versus Placebo

NCT02099084
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Teduglutide, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 21, 2016 · Synced Sep 12, 2026, 5:07 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial

NCT06162715
View directory record Official record
Conditions
Severe Obesity, Obesity, BMI Greater Than 30
Interventions
Tirzepatide, Standard of Care post-gastric bypass
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
25 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 12, 2026, 5:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)

NCT02759107
View directory record Official record
Conditions
Healthy, Type 2 Diabetes Mellitus (T2DM)
Interventions
Tirzepatide, Placebo, Dulaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years to 70 Years
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 15, 2024 · Synced Sep 12, 2026, 5:07 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Pilot Study of the Effects on Sleep Disordered Breathing (SDB) When Using the Drug Liraglutide for 4 Weeks

NCT01832532
View directory record Official record
Conditions
Sleep Apnea, Sleep Disordered Breathing
Interventions
liraglutide
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 60 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Sep 12, 2026, 5:07 AM EDT
Completed Phase 3 Interventional

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

NCT06221969
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Cagrilintide, Semaglutide, Tirzepatide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,024 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
117
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 12, 2026, 5:07 AM EDT
Completed Not applicable Interventional

Randomized Trial of ERCP Then Laparoscopic Cholecystectomy vs. Laparoscopic Cholecystectomy Plus Laparoscopic Common Bile Duct Exploration in Patients With Likely Choledocholithiasis

NCT00807729
View directory record Official record
Conditions
Choleclithiasis, Common Bile Duct Stones
Interventions
ERCP, LapCBDE
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 2, 2009 · Synced Sep 12, 2026, 5:07 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects

NCT02802514
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Albiglutide 50mg, Albiglutide matching placebo, Exenatide 10microgram, Exenatide placebo (saline)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Sep 12, 2026, 5:07 AM EDT
Completed Not applicable Interventional Results available

The Monitoring Study

NCT02969863
View directory record Official record
Conditions
Type1diabetes
Interventions
Bihormonal Bionic Pancreas, Insulin Only Bionic Pancreas, Monitored for Hypoglycemia, Not Monitored for Hypoglycemia
Device · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 29, 2018 · Synced Sep 12, 2026, 5:07 AM EDT
Completed Phase 4 Interventional Results available

A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America

NCT05579249
View directory record Official record
Conditions
Obesity
Interventions
Semaglutide, Orlistat, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 12, 2026, 5:07 AM EDT
Completed Phase 3 Interventional

A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

NCT06047548
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
20
States / cities
Pelham, Alabama • Los Angeles, California • Santa Ana, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Sep 12, 2026, 5:07 AM EDT
Terminated Phase 3 Interventional Results available

To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c

NCT00294723
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, glimepiride, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
746 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
102
States / cities
Concord, California • Escondido, California • Fullerton, California + 83 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Sep 12, 2026, 5:07 AM EDT
Completed Phase 3 Interventional Results available

Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes

NCT00518882
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, exenatide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
61
States / cities
Birmingham, Alabama • Goodyear, Arizona • Artesia, California + 54 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Sep 12, 2026, 5:07 AM EDT
Recruiting Phase 2 Interventional

Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults

NCT06811324
View directory record Official record
Conditions
Obesity Prevention, Sarcopenia in Elderly, Cardiovascular Function, GLP - 1, Weight Loss
Interventions
Tirzepatide
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 12, 2026, 5:07 AM EDT
Active, not recruiting Phase 3 Interventional

A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight

NCT06962280
View directory record Official record
Conditions
Type 1 Diabetes, Obesity, Overweight
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
18
States / cities
Bonita, California • Escondido, California • Newport Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 12, 2026, 5:07 AM EDT
Recruiting Phase 2 Interventional

Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity

NCT07228741
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Obesity
Interventions
Tirzepatide, Resistance Exercise, Lifestyle Counseling
Drug · Behavioral
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 12, 2026, 5:07 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Effect of GLP-1 on Postprandial Lipid Metabolism

NCT01760772
View directory record Official record
Conditions
Heart Disease
Interventions
Exendin-9, GLP-1, saline
Drug · Other
Lead sponsor
David Dalessio
Other
Eligibility
40 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Sep 12, 2026, 5:07 AM EDT
Completed Phase 3 Interventional Results available

LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.

NCT02964247
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
56
States / cities
Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Sep 12, 2026, 5:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Liraglutide on Heart Frequency in Healthy Volunteers

NCT01516255
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, placebo, moxifloxacin, electrocardiogram (ECG)
Drug · Procedure
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Sep 12, 2026, 5:07 AM EDT